8-K current report · filed Nov 6, 2026

Humana (HUM) 8-K Current Report: November 6, 2026

Item 2.02Item 7.01Item EX-99.3Item EX-99.1Item EX-99.2HUM overview

Short answer

Humana (HUM) filed an 8-K current report with the SEC on November 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.3 (Exhibit EX-99.3), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Humana reported financial results for the quarter ended September 30, 2026.

Humana 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Humana reported financial results for the quarter ended September 30, 2026
  • Detailed earnings release attached as Exhibit 99.1 and Exhibit 99.2
  • Management prepared remarks include expectations for future earnings, attached as Exhibit 99.3

Item 7.01 · Regulation FD Disclosure

  • Q3 2026 financial results released for quarter ended September 30, 2026
  • Detailed earnings release available in Exhibit 99.2 and Humana Investor Relations
  • Management remarks include Q3 results and future earnings expectations in Exhibit 99.3

Item EX-99.1 · Exhibit EX-99.1

  • 3Q26 GAAP EPS $1.33, down from $1.62, while Adjusted loss per share was $0.70 versus $3.24 adjusted earnings
  • Insurance benefit ratio 93.7%, better than guidance of slightly above 94%, but segment operating income fell to a $303 million loss
  • FY2026 Adjusted EPS guidance raised to at least $9.50 from $9.00, despite Star Ratings headwinds
  • FY2026 GAAP EPS guidance raised to at least $15.09 from $6.52, primarily reflecting noncash valuation effects
  • CenterWell patients increased 146,800, or 30%, while Medicaid membership grew 103,600, or 7% year to date

Item EX-99.2 · Exhibit EX-99.2

  • 3Q26 revenue $41.2B, up from $32.6B, but adjusted loss $0.70 per share versus $3.24 earnings
  • Insurance benefit ratio 93.7%, better than guidance of slightly above 94%, despite Star Ratings revenue pressure
  • FY2026 adjusted EPS guidance raised to at least $9.50 from $9.00, while GAAP guidance rose to at least $15.09 from $6.52
  • CenterWell Senior Primary Care patients grew 30% year to date, adding 146,800 patients
  • BlackRock joint venture replaced prior Welsh Carson JVs, reversing approximately $1.2B of put liability and improving balance-sheet flexibility

Item EX-99.3 · Exhibit EX-99.3

  • FY 2026 Adjusted EPS guidance raised from at least $9.00 to at least $9.50, signaling stronger near-term earnings momentum
  • 3Q26 Adjusted loss per share of $0.70 beat expected loss of approximately $1.00, driven by Insurance performance
  • Insurance benefit ratio 93.7%, better than guidance of slightly above 94%, with medical and pharmacy trends high single digit or better
  • Individual MA membership grew 23% to approximately 1,208,000 year to date, expanding scale but increasing execution exposure
  • Balance-sheet improvement: debt-to-capitalization ratio 40.9%, with CenterWell-BlackRock JV expected to reduce it approximately 130 basis points in 4Q26

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Humana 8-K filings

Get the next HUM 8-K as it lands

Follow HUM for push alerts, or ask the research agent what this filing means.